741698-83-9

Upstream product

• 81090-34-8 4-bromo-2-isopropyl-aniline 
• 124-38-9 carbon dioxide 
• 1147014-97-8 4-bromo-1-iodo-2-isopropylbenzene 
• 643-28-7 2-isopropylaniline 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 74-88-4 methyl iodide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 643094-19-3 methyl 4-bromo-2-isopropylbenzoate 

Relevant academic research and scientific papers

CYCLIC AMIDE DERIVATIVE

Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C6-10 arylene, etc.; R1a, R1b and R1c each independently is a hydrogen atom, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, etc.; R2 is an optionally substituted C6-10 aryl group, an optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C7-16 aralkyl group, etc.; m is 0, etc.; n is an integer of 0 to 2.)

Subtle "supramolecular buttressing effects" in Cucurbit[7]uril/guest assemblies

Biphenyl derivatives bearing a dimethylsulfonium group at position 3 and three different substituents at position 4 (H, F and CH3) have been prepared as probes to test the validity of the "supramolecular buttressing" concept. We define the latter as the alteration, by a neighboring unit, of a substituent effect on intermolecular recognition. In this case, the 4-substituents exert some pressure on the 3-dimethylsulfonium groups and control the ratio of their syn and anti conformations. As free species, biphenyls bearing 4-H and 4-F substituents are present as approximately equimolar mixtures of syn and anti-conformers, while the biphenyl scaffold with a 4-CH3 group adopts the anti-conformation exclusively. The 3-dimethylsulfonium substituents then interact with one of the carbonylated portals of Cucurbit[7]uril (CB[7]), and their conformations affect the position of the guests inside the cavity of the macrocycle, thereby validating our "supramolecular buttressing" model. Surprisingly however, binding affinities towards CB[7] are barely affected by the nature of the 4-substituents and the conformations of the neighboring sulfonium groups, despite very different electronic densities presented to the CB[7] portal in their syn or anti conformations. Solvation was found to dramatically smoothen host-guest Columbic interactions, although the latter remain important in the recognition process. Replacing the positively charged 3-dimethylsulfonium unit with an isopropyl substituent decreases the affinity of the biphenyl guest by 1000-fold. The Royal Society of Chemistry 2013.

1H-PYRROLO[2,3-B]PYRIDINES

Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.

AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE

The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF

The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen or lower alkyl; R3 R4, R5 and R6 are each hydrogen, halogen, lower alkyl or lower alkoxy; R7 and R8 are each hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, cyano, a hydroxyl group, lower acyl, carboxy or the like; R9 is -C(O)-R10, -A1-C(O)-R10, -O-A2-C(O)-R10 or a tetrazol-5-yl group, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.